Kura Oncology posts $9.1 million in KOMZIFTI revenue in second quarter of 2026
The company reported majority share of new patient starts in its menin inhibitor class and $519 million in cash to fund the ziftomenib program toward 2028 Phase 3 results.
Kura Oncology reported second quarter 2026 results on August 12, 2026, saying KOMZIFTI generated $9.1 million in net product revenue, a 57% increase from 1Q 2026, with approximately 115 new patient starts, a 35% increase from 1Q, and more than 250 total prescriptions, a 59% increase from 1Q. In its second full quarter on the market, KOMZIFTI achieved a majority share of new patient starts in the R/R NPM1-m AML menin inhibitor class.1
On the clinical side, the company said long-term KOMET-007 data presented at EHA 2026 showed 600 mg ziftomenib plus intensive chemotherapy (7+3) produced CRc rates of 96% and 90% in newly diagnosed NPM1-m or KMT2A-r AML patients, respectively, with 12-month OS rates of 94% and 71%, deep MRD negativity and no new safety signals.1 A June 2026 Blood publication reported updated KOMET-007 results with 600 mg ziftomenib plus venetoclax and azacitidine in R/R NPM1-m AML, where venetoclax-naive patients achieved an 87% ORR and 70% CRc rate, with 75% of composite complete responders achieving central MRD negativity, a median duration of CRc of 9.2 months, and median OS not reached after 10.7 months of follow-up, with generally good tolerability.1
For darlifarnib, Kura cited Phase 1 FIT-001 data showing tumor shrinkage in 77% of response-evaluable patients treated with darlifarnib plus adagrasib, with confirmed ORRs of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naive colorectal cancer1, and separately reported a 44% ORR, 94% disease control rate, and tumor shrinkage in 75% of patients in cabozantinib-exposed clear cell renal cell carcinoma patients treated with darlifarnib plus cabozantinib1.
On finances, the company reported $519.0 million in cash, cash equivalents and short-term investments as of June 30, 2026, compared to $667.2 million as of December 31, 20251. Kura said combined with $180 million in anticipated collaboration payments from Kyowa Kirin, it believes current cash resources will be sufficient to fund the ziftomenib AML program through topline results from the first pivotal Phase 3 KOMET-017 trial, anticipated in 2028.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.